Live feed06:00:00·26dPRReleasevia QuantisnowIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung CancerByQuantisnow·Wall Street's wire, on your screen.IDYA· IDEAYA Biosciences Inc.Health Care
